Abstract
Iminium quaternary protoberberine alkaloids (QPA) have been found to be novel P2X(7) antagonists. To assess their structure-activity relationships, these compounds were modified at their R(1) and R(2) groups and assayed for their ability to inhibit the 2'(3')-O-(4-benzoylbenzoyl)-ATP (BzATP)-induced uptake of fluorescent ethidium by HEK-293 cells stably expressing the human P2X(7) receptor, and their ability to inhibit BzATP-induced IL-1beta release by differentiated THP-1 cells. Compounds 15a and 15d, with alkyl groups at the R(1) position, and especially compound 19h, with the 2-NO(2)-4,5-dimethoxy-benzyl group at the R(2) position, had potent inhibitory efficacy as P2X(7) antagonists.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives
-
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / chemistry
-
Alkaloids / chemistry
-
Berberine Alkaloids / pharmacology
-
Cell Differentiation
-
Cell Line
-
Chemistry, Pharmaceutical / methods*
-
Drug Design
-
Ethidium / chemistry
-
Ethidium / pharmacokinetics
-
Humans
-
Interleukin-1beta / metabolism
-
Lipopolysaccharides / chemistry
-
Models, Chemical
-
Purinergic P2 Receptor Antagonists*
-
Quinolizines / chemical synthesis*
-
Receptors, Purinergic P2X7
-
Structure-Activity Relationship
Substances
-
5,6-dihydrodibenzo(a,g)quinolizinium
-
Alkaloids
-
Berberine Alkaloids
-
Interleukin-1beta
-
Lipopolysaccharides
-
P2RX7 protein, human
-
Purinergic P2 Receptor Antagonists
-
Quinolizines
-
Receptors, Purinergic P2X7
-
protoberberine
-
KN 62
-
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
-
Ethidium